INHANCE™ Shoulder System by DePuy Synthes

INHANCE™ Shoulder System

The Johnson & Johnson Medical Devices Companies* announced that DePuy Synthes, The Orthopaedics Company of Johnson & Johnson,** introduces the INHANCE™ Shoulder System, a first-to-market, fully integrated shoulder arthroplasty system.

INHANCE™ Shoulder System is designed with an intuitive stemless-first surgical approach that aligns with how surgeons approach patient care. The INHANCE Shoulder System is the first shoulder system to offer surgeons the ability to seamlessly transition from stemless to stemmed implants during surgical procedures.

There are many reasons surgeons may need to transition to a different surgical treatment option during shoulder arthroplasty procedures, including humeral bone quality and severity of glenoid bone loss, or the extent of rotator cuff deficiency.

The INHANCE Shoulder System empowers surgeons to treat a broad range of cases by providing an intelligently-designed implant offering that is both streamlined and comprehensive, and also features unique interoperative flexibility, addressing a critical unmet clinical need. The common instrumentation of the INHANCE Shoulder System also facilitates greater OR efficiency1.

This new class of shoulder system also features:

  • Reusable instrumentation optimized for efficiency with only two instrument cases for stemless and stemmed anatomic procedures
  • A comprehensive size range of anatomic stemless and stemmed inlay humeral implants that share a common geometrical shape to easily fixate to the humerus
  • A unique circular anatomic glenoid component compatible with any sized humeral head, and the ONE STEP PREP™ Glenoid Reamer that reduces the number of surgical steps, eliminating the need to separately ream the backside of the implant, drill the central hole, and drill the peripheral holes2

“Advancements in shoulder arthroplasty have enabled a broader range of surgical treatment over the past decade but have increased the complexity and cost of preparing for each surgical case,” said J. Michael Wiater, MD, Vice Chairman, Chief of Shoulder Surgery and Professor of Orthopedic Surgery, Oakland University William Beaumont School of Medicine***. “The INHANCE™ Shoulder System can empower surgeons to seamlessly alter their surgical flow, while simultaneously keeping their focus on the patient, and has the potential to reduce OR time.”

The INHANCE™ Shoulder System is also designed for the shift in site of care of certain orthopaedic procedures towards outpatient and ambulatory surgery centers where economic value and operational efficiency are critical considerations. The INHANCE Shoulder System’s implants are designed to preserve bone, provide immediate and long-term fixation, and facilitate intra-operative flexibility while simplifying preparation for various surgical treatment options3,4.

Additional features of the system include:

  • Novel implant designs that are additively manufactured via state-of-the-art 3D laser printing incorporating the UNITI™ Porous Structure, which was created specifically for biological fixation in the shoulder.3
  • Only two reusable instrument cases are required, reducing the number of trays needed to be reprocessed, stored, and retrieved
  • Advanced cross-linked Vitamin E polyethylene for desired wear characteristics and oxidative stability, which becomes an important consideration to reduce the risk of revision and complications4, which can potentially reduce the economic burden to the healthcare system.

DePuy Synthes acquired the INHANCE™ Shoulder System through a multi-year, strategic agreement with Ignite Orthopedics, LLC. Through this collaboration, DePuy Synthes will launch the core system plus additional product innovations. The INHANCE Shoulder System was designed in collaboration with a team of leading shoulder arthroplasty surgeons and is competitively positioned to address the increasing complexity of shoulder replacement procedures by integrating less invasive clinical options aligned with how surgeons approach patient care.

“At DePuy Synthes we’re focused on delivering innovations to address the most pressing needs of surgeons today while anticipating market dynamics that drive clinical trends and the needs of tomorrow,” said Russell Powers, Worldwide President, Sports Medicine and Shoulder Reconstruction, DePuy Synthes****. “The INHANCE™ Shoulder System reflects our strong commitment to lead in shoulder arthroplasty by taking innovation to the next level.”


References

1 INHANCE Surgical Step Comparison (Glenoid and Humeral) DPS – 103814569 Rev 1 and DPS – 103814569. See document summary tab.

2 INHANCE Surgical Step Comparison DPS 103814569 Rev 1 -. See document summary tab.

3 Ignite TR-200803 REV 00 – X1 Fine 3D Printed Porous Eval Including Appendix’s’ A thru E

4 Ignite Characterization of AO-HXLPE Report

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version